MedTrace Logo

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-08

No results posted yet for this study

Summary

This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants

Conditions

  • Healthy

Interventions

DRUG

Nirogacestat

oral dose of 150 mg nirogacestat

DRUG

Nirogacestat and Famotidine

oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine

DRUG

Nirogacestat and Rabeprazole

oral dose of 150 mg nirogacestat and oral dose of 20 mg rabeprazole

Sponsors & Collaborators

  • SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Mary Beth Brune, MD · Medpace, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-21
Primary Completion
2025-11-10
Completion
2025-11-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07171619 on ClinicalTrials.gov